Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049896 | 1.00 | DUT (0.44) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15294577 | 0.94 | DUT (0.43) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25400162 | 0.94 | DUT (0.43) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL992733 | 0.94 | DUT (0.43) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL992730 | 0.94 | DUT (0.43) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12049893 | 0.93 | DUT (0.46) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12769585 | 0.93 | DUT (0.46) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL21152138 | 0.90 | DUT (0.44) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25401818 | 0.90 | DUT (0.44) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL10072880 | 0.90 | DUT (0.44) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915232-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | NSUN2, RNGTT, RNMT | DUT 10/4885SLC28A1 56/4885SLC28A2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.